Why Fosun Pharma’s AriBio deal could reshape the race for oral Alzheimer’s therapies
Alzheimer’s drugs are moving beyond antibodies. Fosun Pharma’s AR1001 option turns one Phase 3 readout into a global commercial test.
Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to […]